Vaccinia virus and peptide-receptor radiotherapy synergize to improve treatment of peritoneal carcinomatosis.

Mol Ther Oncolytics · 2023 · PMC10173076 · PMID 37180034

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

The median survival in all treatment groups was increased relative to the HBSS-treated controls (38 days median survival) and was statistically significant in all cases, with the exception of vvDD-EGFP + 177 Lu- DOTATOC (15 MBq) (55 days median survival), which showed a trend toward improvement.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.